利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.018 秒)

    IL-2 transmembrane construct
    1.
    发明授权
    IL-2 transmembrane construct 失效
    IL-2跨膜构建体

    公开(公告)号：US07407777B2

    公开(公告)日：2008-08-05

    申请号：US10548153

    申请日：2004-03-08

    申请人： Wolfram Samlowski ,  Nathan Bradley Adams ,  John McGregor

    发明人： Wolfram Samlowski ,  Nathan Bradley Adams ,  John McGregor

    IPC分类号： C12N5/10 ,  C12N15/62 ,  C12N15/63

    CPC分类号： C07K14/55 ,  A61K38/00 ,  C07K14/70535 ,  C07K2319/03 ,  C07K2319/20

    摘要： Compounds, genetic constructs, and cancer treatment methods are provided. Expression vectors were designed to express fusion genes including hIL-2 with a Fcε-γ transmembrane anchor derived from a subunit of the FC epsilon receptor. mRNA and the IL-2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL-2tm protein on the tumor cell surface membrane was confirmed by microscopy. RD995 cells transfected with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into C3H/HEN mice. Tumors of mice implanted with 106 or 105 RD995 cells transfected with IL-2tm grew slower than controls. It is believed that selective expression of cytokines such as IL-2 on the surface of tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition and killing, potentially avoiding toxicity associated with known cytokine therapies.

    摘要翻译： 提供了化合物，遗传构建体和癌症治疗方法。 设计表达载体用来源自FCε受体亚基的Fcepsilon-gamma跨膜锚来表达包括hIL-2的融合基因。 mRNA和IL-2tm融合蛋白在转染的RD995肿瘤细胞中表达。 通过显微镜证实IL-2tm蛋白在肿瘤细胞表面膜上的表达。 将用IL-2tm或pCMV2b（空载体）转染的RD995细胞皮下植入C3H / HEN小鼠。 植入用IL-2tm转染的10×10 6或10×10 4 RD995细胞的小鼠的肿瘤生长慢于对照。 据信，在肿瘤表面的细胞因子如IL-2的选择性表达可能刺激被引发并已经识别肿瘤抗原的肿瘤浸润淋巴细胞，增强肿瘤识别和杀死，潜在地避免与已知的细胞因子疗法相关的毒性。

    Il-2 transmembrane construct
    3.
    发明申请
    Il-2 transmembrane construct 失效
    II-2跨膜构建体

    公开(公告)号：US20060177908A1

    公开(公告)日：2006-08-10

    申请号：US10548153

    申请日：2004-03-08

    申请人： Wolfram Samlowski ,  Nathan Adams ,  John McGregor

    发明人： Wolfram Samlowski ,  Nathan Adams ,  John McGregor

    IPC分类号： C07K14/54 ,  C07H21/04 ,  C12P21/04

    CPC分类号： C07K14/55 ,  A61K38/00 ,  C07K14/70535 ,  C07K2319/03 ,  C07K2319/20

    摘要： Compounds, genetic constructs, and cancer treatment methods are provided. Expression vectors were designed to express fusion genes including hIL-2 with a Fcε-γ transmembrane anchor derived from a subunit of the FC epsilon receptor. mRNA and the IL-2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL-2tm protein on the tumor cell surface membrane was confirmed by microscopy. RD995 cells transfected with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into C3H/HEN mice. Tumors of mice implanted with 106 or 105 RD995 cells transfected with IL-2tm grew slower than controls. It is believed that selective expression of cytokines such as IL-2 on the surface of tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition and killing, potentially avoiding toxicity associated with known cytokine therapies.

    摘要翻译： 提供了化合物，遗传构建体和癌症治疗方法。 设计表达载体用来源自FCε受体亚基的Fcepsilon-gamma跨膜锚来表达包括hIL-2的融合基因。 mRNA和IL-2tm融合蛋白在转染的RD995肿瘤细胞中表达。 通过显微镜证实IL-2tm蛋白在肿瘤细胞表面膜上的表达。 将用IL-2tm或pCMV2b（空载体）转染的RD995细胞皮下植入C3H / HEN小鼠。 植入用IL-2tm转染的10×10 6或10×10 4 RD995细胞的小鼠的肿瘤生长慢于对照。 据信，在肿瘤表面的细胞因子如IL-2的选择性表达可能刺激被引发并已经识别肿瘤抗原的肿瘤浸润淋巴细胞，增强肿瘤识别和杀死，潜在地避免与已知的细胞因子疗法相关的毒性。